Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2022 Jan 1;89(1):49–55. doi: 10.1097/QAI.0000000000002821

Figure 4:

Figure 4:

Overlap between individuals selected under two prioritization schemes: clusters with high growth at 0.5% (g0.5%) and recent and rapid clusters with at least 3 diagnoses in the previous year (RR3). Note that the number of individuals selected under the growth schemes was determined based on the number of individuals in the RR3 group (~150), but the RR3 group can only include individuals diagnosed within the previous three years.